key: cord-0773680-x21g6i3g
authors: Soresina, Annarosa; Moratto, Daniele; Chiarini, Marco; Paolillo, Ciro; Baresi, Giulia; Focà, Emanuele; Bezzi, Michela; Baronio, Barbara; Giacomelli, Mauro; Badolato, Raffaele
title: Two X‐linked agammaglobulinemia patients develop pneumonia as COVID‐19 manifestation but recover
date: 2020-05-19
journal: Pediatr Allergy Immunol
DOI: 10.1111/pai.13263
sha: d9c10cc9cfcc515e570dc8523262c88c0d4ccdc7
doc_id: 773680
cord_uid: x21g6i3g

BACKGROUND: The recent SARS‐CoV‐2 pandemic, which has recently affected Italy since February 21, constitutes a threat to normal subjects, as the coronavirus disease‐19 (COVID‐19) can manifest with a broad spectrum of clinical phenotypes ranging from asymptomatic cases to pneumonia or even death. There is evidence that older age and several comorbidities can affect the risk to develop severe pneumonia and possibly the need of mechanic ventilation in subjects infected with SARS‐CoV‐2. Therefore, we evaluated the outcome of SARS‐CoV‐2 infection in patients with inborn errors of immunity (IEI) such as X‐linked agammaglobulinemia (XLA). METHODS: When the SARS‐CoV‐2 epidemic has reached Italy, we have activated a surveillance protocol of patients with IEI, to perform SARS‐CoV‐2 search by nasopharyngeal swab in patients presenting with symptoms that could be a manifestation of COVID‐19, such as fever, cough, diarrhea, or vomiting. RESULTS: We describe two patients with X‐linked agammaglobulinemia (XLA) aged 34 and 26 years with complete absence of B cells from peripheral blood who developed COVID‐19, as diagnosed by SARS‐CoV‐2 detection by nasopharyngeal swab, while receiving immunoglobulin infusions. Both patients developed interstitial pneumonia characterized by fever, cough, and anorexia and associated with elevation of CRP and ferritin, but have never required oxygen ventilation or intensive care. CONCLUSION: Our report suggests that XLA patients might present with high risk to develop pneumonia after SARS‐CoV‐2 infection, but can recover from infection, suggesting that B‐cell response might be important, but is not strictly required to overcome the disease. However, there is a need for larger observational studies to extend these conclusions to other patients with similar genetic immune defects.

Since February 21, 2020, several cases of coronavirus disease 2019 , caused by the β-coronavirus associated with human severe acute respiratory syndrome (SARS) officially named SARS-CoV-2, were identified in northern Italy. 1 The disease has a broad spectrum of clinical phenotypes ranging from mild symptomatic cases characterized by influenza-like manifestations, which occur in the majority of subjects (about 80%), to severe pneumonia requiring admission to intensive care units in 5% or invasive mechanical ventilation, or even death. 2 Patients with severe disease usually present with comorbidities and are older than those with non-severe disease. Most of the COVID-19 patients exhibit lymphopenia, which is more pronounced in severe cases; thrombocytopenia; and elevation of C-reactive protein. The disease has an incubation period of 5-14 days and manifests with fever, cough, vomiting, and diarrhea lasting up to 2-3 weeks.

Little is known about the mechanism of immune response against the SARS-CoV-2, but the first reports suggest that active immunity requires the formation of antigen-specific cytotoxic T cells and synthesis of neutralizing antibodies directed against the virus. 3, 4 There is no specific antiviral treatment for patients with this infection, but many antiviral or immunomodulatory drugs are under evaluation. 5, 6 Indeed, patients with severe COVID-19 have been successfully treated with immune plasma derived from convalescent patients, suggesting that virus-specific neutralizing antibodies are important for disease recovery. 7, 8 

After the identification of patients with SARS-CoV-2 infection in Italy, we started a survey protocol on patients with chronic diseases who presented with COVID-19 to identify conditions that could constitute a risk factor for an unfavorable outcome. SARS-CoV-2 infection was confirmed in all patients by the detection of viral RNA by real-time reverse transcription polymerase chain reaction (RT-PCR) assay in nasopharyngeal swab specimens obtained during the clinical manifestations. Patient care and research were conducted in compliance with the Case Report guidelines and the Declaration of Helsinki. This study was performed after ethics approval (Ethics Committee of Brescia, protocols NP4000 and NP4047).

Herein we describe two patients with agammaglobulinemia and absence of circulating B cells due to BTK mutations who live in northern Italy and have developed COVID-19 during the 2020 outbreak. In the following days, the patient presented with fever, but he never required oxygen supplementation. We started treatment with hydroxychloroquine, azithromycin, and ceftriaxone and administered immunoglobulin infusion at 400 mg/kg. In the following days, his conditions have been improving. Flow cytometry analysis of lymphocyte subpopulations, which was performed 7 days before the appearance of the first symptom, showed normal distribution of T and NK subsets (Table 2 ).

We describe two patients with XLA who have been exposed to SARS-CoV-2 and developed interstitial pneumonia and lymphopenia. Despite the absence of B cells, both subjects could recover without the need for intensive care or oxygen ventilation. This observation suggests that T-cell response is probably important for immune protection against the virus, while B-cell response might be unessential. This is in agreement with preliminary studies that have shown that in normal subjects infected by SARS-CoV-2, the number of cytotoxic T cells expressing activation markers such as HLA-DR and CD38 increases during infection. 4 However, the risk to develop pneumonia after SARS-CoV-2 infection is quite low in young adults such as the two XLA patients, suggesting that the lack of antibody production is probably contributing to disease severity. Moreover, there is also evidence that passive antibody administration through transfusion of convalescent plasma constitutes a feasible strategy to confer immunization to patients with severe COVID-19 and contributes to improve the clinical manifestations and the outcome of these subjects, suggesting that production of neutralizing antibodies might also be an important step for disease recovery. 7, 8 Therefore, the lack of neutralizing antibodies in XLA patients might place these subjects at higher risk of disease relapse, suggesting the need for careful monitoring during convalescence.

The observation that patients with X-linked agammaglobulinemia can recover from SARS-CoV-2 infection suggests that human immune system could use multiple paths to counteract viral infection and that a normal T-cell immune response can be sufficient to defeat the virus in subjects who cannot synthesize antigen-specific immunoglobulins.

However, BTK is expressed not only in B cells, but also in myeloid cells. In these cell types, BTK is involved in Toll-like receptor-mediated production of pro-inflammatory cytokines, such as IL-6 and TNF-α, which are produced in large amount in patients with SARS-CoV-2 infection. 9 Therefore, the lack of BTK in myeloid cells of XLA patients might provide a subordinate advantage for these patients 

Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe

Functional exhaustion of antiviral lymphocytes in COVID-19 patients

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

Current drugs with potential for treatment of COVID-19: a literature review

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

Deployment of convalescent plasma for the prevention and treatment of COVID-19

Tolllike receptor 4-, 7-, and 8-activated myeloid cells from patients with X-linked agammaglobulinemia produce enhanced inflammatory cytokines

Bruton tyrosine kinase (BTK) in X-linked agammaglobulinemia (XLA)

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet Respiratory Medicine

COVID-19: consider cytokine storm syndromes and immunosuppression

Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover